

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視醫療科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT RIGID CONTACT LENSES OBTAINED NMPA MEDICAL DEVICE REGISTRATION CERTIFICATE

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, on October 27, 2023, the rigid contact lenses self-produced by Gaush Clear Ltd.* (蘇州高視高清醫療技術有限公司) (the “**Suzhou Gaush Clear**”), a subsidiary of the Company, has obtained the medical device registration certificate issued by the National Medical Products Administration (NMPA) of the People’s Republic of China (the “**PRC**”).

Myopia has become one of the important social issues among children and youth in the PRC. Currently, the myopia rate of children and youth in the PRC reached approximately 52.7% and meanwhile there is a trend of myopia in the young age group. Also, the ratio of high myopia remains at a high level. According to the “Report on the Prevention and Control of Myopia among Children and Youth in the Informationalized Era” (《信息化時代兒童青少年近視防控報告》) issued in 2021, the future myopia population in the PRC will reach at least 0.96 billion. According to a special myopia research, nearly 10% of the myopia students are high myopia and such percentage increases as the students move onto higher grades. Among six-year-old kindergarteners, 1.5% of the population is high myopia, and such percentage reaches 17.6% among high school students. High myopia is prone to severe complications such as cataract, retinal detachment and glaucoma etc., which are eye diseases that could lead to total blindness and are focuses of prevention and control in the PRC.

The “White Paper of Myopia Management — Experts Consensus (2019)” states that rigid gas permeable contact lenses (RGP) are one of the procedures to correct non-progressive myopia. Rigid contact lenses are applicable to patients with high myopia, high hyperopia, irregular astigmatism, anisometropia and keratoconus. Rigid contact lenses are made with materials with high oxygen permeability, and their characteristics of high oxygen permeability made them more healthy and safe to wear. While feeling a bit of discomfort at the beginning, patients will need some time to adapt.

Rigid contact lenses produced by Suzhou Gaush Clear have applied, for the first time, the patented design of large optical area and three-segment gentle edge arc design that transitions smoothly from the inside out, to enhance clarity and vision quality as well as tears exchange, while eliminating the discomfort while wearing, making them even more comfortable and safe.

Rigid contact lenses are an effective measure to correct myopia, their corrective result has been certified by global clinical results, with their market scale gradually expanding in the future. Our rigid contact lenses receiving the medical device registration certificate enriches the product portfolio of the Group and materializes the diversified product layout of the Group.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, November 2, 2023

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* *For identification purposes only*